Skip to main content
. 2000 Dec;44(12):3408–3413. doi: 10.1128/aac.44.12.3408-3413.2000

TABLE 3.

Assessment of efficacy in ITT, clinically evaluable, and microbiologically evaluable patients

Patient group Treatment Total no. (%) of patients assesseda No. (%) of patients with assessment
P (95% CIb [point estimate])b
Cure Failurec
ITT Linezolid 400 (100) 279 (69.8) 121 (30.8) 0.141 (−1.58, 11.25 [4.9])
Oxacillin-dicloxacillin 419 (100) 272 (64.9) 147 (35.1)
Clinically evaluable Linezolid 298 (100) 264 (88.6) 34 (11.4) 0.300 (−2.5, 8.2 [2.8])
Oxacillin-dicloxacillin 302 (100) 259 (85.8) 43 (14.2)
Microbiologically evaluable Linezolid 143 (100) 126 (88.1) 17 (11.9) 0.606 (−5.6, 9.7 [2.0])
Oxacillin-dicloxacillin 151 (100) 130 (86.1) 21 (13.9)
a

Percentages based on number of assessed patients. 

b

Confidence interval based on normal approximation, expressed as a percentage. 

c

Includes patients with missing or indeterminate outcomes. 

HHS Vulnerability Disclosure